DISTRIBUTION OF CD4+ RORg-T Th17 AND CD25+ FOXP3+ Treg IN LEPROSY PATIEN WITH REVERSAL REACTION
DOI:
https://doi.org/10.66344/jpad.v28i2.1102Keywords:
CD4 RORg-T Th17, CD25 FOXP3 Treg, IL17, Reversal Reaction, Erythema Nodosum LeprosumAbstract
Objective To compare the distribution of CD4+ Th17 and CD25+ FOXP3 T regulatory cell (Treg) between type I reversal reaction (RR) and type II reversal reaction i.e. erythema nodosum leprosum (ENL) patient groups.
Methods A total of 50 samples, consisted of 27 samples of reversal reaction (RR) and 23 samples of ENL, were collected. Observation of CD4+ RORg-T Th17 and CD25+ FOXP3 Treg were conducted with immunohistochemistry staining technique using anti FOX-P3 and anti RORg-T. Expression of CD4+ ROR-g Th17 and CD25+ FOXP3 Treg in percentage were analyzed using T-test.
Results There is a significant difference in mean CD4+ ROR-g Th17 and IL17 cell distribution for RR patient group (14.96% and 10.72%) compared with ENL (9.12% and 4.28%). No significant difference were found between mean CD25+ FOXP3 Treg and TGF-β cell distribution in RR patient group (6.12% and 5.44%) compared with ENL group (6.16% and 5.96%).
Conclusion There is a significant increment od CD+RORg-T Th17 and IL17 in RR patients group compared with ENL patients group. however, the distribution of CD25+ FOXP3+ Treg and TGF beta in RR has no significant difference compared with ENL.
References
1. WHO Expert Committee on leprosy. Eight report. Geneva, World Health Organization, 2002. WHO Technical Report Series, No. 968.
2. Worobec SM. Current approaches and future directions in the treatment of leprosy. Trop Med. 2012;3:79-91.
3. Walker SL, Lockwood DNJ. (2006). The Clinical and immunological features of leprosy. Br Med Bull. 2006;77-78:103-21.
4. Pandhi D, Chhabra N. New Insights in The Pathogenesis of Type 1 and Type 2 Lepra Reaction. Indian J Dermatol Venereol Leprol. 2013;79:739-749.
5. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345-50.
6. Saini C, Ramesh V, Nath I. CD4+ Th17 cells discriminate clinical types and constitute a third subset of non Th1, non Th2 T cells in human leprosy. PLoS Negl Trop Dis. 2013;7(7):e2338.
7. Sadhu S, Khaitan BK, Joshi B, Sengupta U, Nautiyal AK, Mitra DK. Reciprocity between regulatory T cells and Th17 cells: Relevance to polarized immunity in leprosy. PLoS Negl Trop Dis. 2016;10(1): e0004338.
8. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013;14:307-8.
9. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531-64.
10. Nath I, Van Rood JJ, Mehra NK, Vaidya MC. Natural suppressor cells in human leprosy: the role of HLA-D-identical peripheral lymphocytes and macrophages in the in vitro modulation of lymphoproliferative responses. Clin Exp Immunol. 1980;42:203-10.
11. Saini C, Siddiqui A, Ramesh V, Nath I. Leprosy reactions show increased Th17 cell activity and reduced FOXP3+ Tregs with concomitant decrease in TGF-beta and increase in IL-6. PLoS Negl Trop Dis. 2016;10(4):e0004592.
12. Vieira AP, Trindade MÂ, Pagliari C, Avancini J, Sakai-Valente NY, Duarte AJ et al. Development of type 2, but not type 1, leprosy reactions is associated with a severe reduction of circulating and in situ regulatory T-cells. Am J Trop Med Hyg. 2016;94:721-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Renni Yuniati, Riawan, Widasmara D, Darmaputra IGN, Arifin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
